Mixed Deck — All CTA Topics Flashcards

What is a confidence interval (CI) used for in clinical trial reporting?

Answer: To express the range within which the true treatment effect likely falls

A confidence interval provides a range of plausible values for the true treatment effect, with a 95% CI meaning the true value falls within that range 95% of the time.

A CTA notices that the same site coordinator has been entering data for multiple subjects simultaneously using different browser tabs in the eCRF. What concern does this raise?

Answer: Risk of data entry errors due to cross-contamination of subject data across tabs

Entering data for multiple subjects simultaneously across browser tabs increases the risk of entering the wrong data for the wrong subject, compromising data integrity.

What is the purpose of a Protocol Deviation Report (PDR) in a clinical trial?

Answer: To document and communicate any departure from the approved protocol

A PDR documents and communicates any departure from the approved protocol to the sponsor and, when required, to the IRB/ethics committee.

During a protocol review, a CTA notices that the washout period between study treatments appears too short to eliminate carryover effects. What should the CTA do?

Answer: Document the concern and escalate to the clinical team or medical monitor for review

The CTA should document the concern and escalate to the appropriate clinical team members for scientific and medical review.

When a CTA performs source data verification (SDV), what is being confirmed?

Answer: That CRF data accurately reflects the source documents from which it was transcribed

SDV confirms that data entered into the CRF is consistent, complete, and accurate when compared to the original source records.

What is the Medical Dictionary for Regulatory Activities (MedDRA)?

Answer: A standardized international medical terminology used to code adverse events and medical conditions in clinical trials

MedDRA is a globally harmonized, standardized medical terminology used by regulatory authorities and the pharmaceutical industry to code clinical data, including adverse events, in a consistent manner.

Which phase of clinical trials primarily assesses the drug’s safety?

Answer: Phase I

Phase I clinical trials are the initial stage of human testing for a new drug or treatment, typically involving a small number of healthy volunteers or patients. The primary objective of these studies is to assess the drug's safety profile, determine a safe dosage range, and identify potential side effects. Efficacy is not the main focus at this early stage.

Under 21 CFR Part 312.62, investigators are required to retain records for clinical investigations for how long after the investigation is discontinued or completed?

Answer: 2 years

21 CFR Part 312.62 requires investigators to retain records for two years after a marketing application is approved or the investigation is discontinued, whichever is later.

What is the purpose of a Clinical Study Report (CSR) as defined by ICH E3?

Answer: To provide an integrated report of the trial's methods, results, and conclusions

ICH E3 defines the CSR as a comprehensive document integrating study methods, clinical results, and statistical analyses to support regulatory submissions.

In Good Clinical Practice, the term 'essential documents' refers to which of the following?

Answer: Documents that individually and collectively permit evaluation of the conduct of the trial and the quality of the data produced

ICH E6 defines essential documents as those that permit evaluation of trial conduct and data quality, and they must be retained in both investigator and sponsor trial master files.

ICH E6(R2) requires that informed consent be obtained before which of the following?

Answer: Before any trial-specific procedures are performed

GCP mandates that informed consent must be obtained prior to any trial-specific screening or treatment procedures being conducted.

Which standard of practice is MOST important for ensuring quality in Good Clinical Practice & ICH Guidelines?

Answer: Following evidence-based protocols while adapting to specific circumstances

Evidence-based protocols provide a foundation of proven practices, but effective Clinical Trial Associate professionals must also adapt their approach based on specific circumstances and individual case needs within Good Clinical Practice & ICH Guidelines.

What is a Dear Healthcare Provider (DHCP) letter used for in drug safety?

Answer: To communicate important new safety information about a marketed product to prescribers

A DHCP letter (also called a Dear Doctor letter) is a risk communication tool used to rapidly disseminate important safety information about a marketed drug to prescribers and other healthcare professionals.

The term 'database lock' in clinical trial data management refers to:

Answer: Freezing the clinical database after all data cleaning is complete so no further changes can be made before analysis

Database lock is the formal process of declaring all data clean and complete, then restricting further edits so that statistical analysis proceeds on a final, verified dataset.

Which document provides the rationale for the investigational product dose, formulation, and route of administration?

Answer: Investigator Brochure

The Investigator Brochure compiles preclinical and clinical data to support the proposed dosing and administration regimen.

What should be done if a data entry error is found in a CRF?

Answer: Correct it, date it, and explain the change

When a data entry error is found in a CRF, it must be corrected in a way that maintains an audit trail and ensures data integrity. The correct procedure involves drawing a single line through the incorrect entry, writing the correct information, dating the change, and initialing it, often with a brief explanation for the modification. This ensures the original entry remains legible and the change is transparent and attributable.

What information must be documented each time investigational product is dispensed to a trial participant?

Answer: Participant ID, date, kit or lot number, dose dispensed, quantity, and the name of the person who dispensed it

Each dispensing entry must capture who received the IP, when, what was given (lot/kit number, dose, quantity), and who dispensed it to create a complete, auditable accountability record.

What is the role of a Clinical Trial Agreement (CTA) between a sponsor and an institution during study startup?

Answer: It establishes legal and financial terms governing the conduct of the trial at the site

The Clinical Trial Agreement is a legal contract outlining financial, intellectual property, publication rights, and liability terms between the sponsor and site.

A sponsor wants to claim a new indication for an already-approved drug. Which type of NDA/BLA submission is most appropriate?

Answer: Efficacy Supplement

An Efficacy Supplement is required when adding a new indication, which involves new clinical data supporting the change.

What distinguishes a surrogate endpoint from a clinical endpoint in trial design?

Answer: Surrogate endpoints measure a biomarker expected to predict clinical benefit rather than direct patient outcomes

Surrogate endpoints, such as tumor shrinkage or biomarker levels, are used as proxies for clinical outcomes like survival when direct measurement would require too long a follow-up.